Excess Ticagrelor Mortality: Reporting Bias or a Canary in the Coal Mine? - 26/07/17
Doi : 10.1016/j.amjmed.2017.02.050
El texto completo de este artículo está disponible en PDF.
| Funding: No funding received. |
|
| Conflict of Interest: OH is a former employee of AstraZeneca and owns stock in AstraZeneca. From 2005 to 2011, OH was a member of the global ticagrelor product team with responsibility for the Health Economics and Outcome Research aspects of the ticagrelor development program. OH is the owner/operator of Hauch Consultancy, Rue De Bordeaux 54, St. Gilles, Belgium. Hauch Consultancy does not have AstraZeneca as a client and OH has not worked for AstraZeneca since he left AstraZeneca in December of 2015. |
|
| Authorship: The author is solely responsible for writing this manuscript. |
© 2017
Elsevier Inc. Reservados todos los derechos.
Vol 130 - N° 8
P. e351 - août 2017 Regresar al número
Artículo precedente
- The Reply
- Aakash Garg, Abhishek Sharma
- The Reply
- Victor L. Serebruany, Thomas A. Marciniak
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?